SCHEMBL30101385

SCHEMBL30101385

CN(C)C1CCN(c2cccc3c2CNC3)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 7/20 0.48
CYP2D6 P10635 4/20 0.48
PIM1 P11309 1/20 0.45
PIM3 Q86V86 1/20 0.45
PIM2 Q9P1W9 1/20 0.45
CYP2C9 P11712 1/20 0.42
TIPARP Q7Z3E1 1/20 0.41
DPP4 P27487 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
MAP4K4 O95819 1/20 0.34
HTR1D P28221 2/20 0.34
HTR3A P46098 2/20 0.34
HTR6 P50406 2/20 0.34
TMEM97 Q5BJF2 2/20 0.34
MCHR1 Q99705 1/20 0.34
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34
HTR1B P28222 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30101383 0.92 CXCR4 (0.48) CXCR4CYP2D6PIM1PIM3PIM2
SCHEMBL21743768 0.88 CXCR4 (0.48) CXCR4CYP2D6PIM1PIM3PIM2
SCHEMBL21743765 0.80 CXCR4 (0.48) CXCR4CYP2D6CYP2C9TIPARPHTR2C
SCHEMBL24913825 0.74 SMARCA2 (0.39) TIPARPHTR2CHTR2BCHRM2CHRM4
SCHEMBL31062432 0.74 SMARCA2 (0.39) TIPARPHTR2CHTR2BCHRM2CHRM4
SCHEMBL10269536 0.73 DRD3 (0.49) CXCR4CYP2D6TIPARPHTR2AHTR2C
Hydrochloric Acid SCHEMBL30368686 0.73 SMARCA2 (0.39) TIPARPHTR2CHTR2BCHRM2CHRM4
Hydrochloric Acid SCHEMBL29008605 0.73 SMARCA2 (0.39) TIPARPHTR2CHTR2BCHRM2CHRM4
SCHEMBL13128616 0.72 HTR6 (0.41) HTR2BHTR6MCHR1KCNH2
SCHEMBL17955710 0.72 PIM1 (0.51) PIM1PIM3PIM2HTR1DHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 CXCR4 2998/4885CYP2D6 533/4885PIM1 933/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 CXCR4 2998/4885CYP2D6 533/4885PIM1 933/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 CXCR4 2998/4885CYP2D6 533/4885PIM1 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.